Impax Laboratories, Inc., based in Hayward, CA, today announced that the U.S. FDA has approved the Company’s supplemental new drug application (sNDA) for EMVERM (mebendazole) 100 mg chewable tablets.  EMVERM is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Pinworm is a highly contagious parasite that infects approximately 40 million people in the United States each year.  Pinworm infection is three times more common than head lice.  

 

Source:

http://investors.impaxlabs.com/Media-Center/Press-Releases/Press-Release-Details/2016/Impax-Receives-Approval-of-EMVERM-mebendazole-Chewable-Tablets-100-mg/default.aspx